Screening for brain metastases in patients with stage III non –small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study
Non –small-cell lung cancer (NSCLC) guidelines advise to screen stage III NSCLC patients for brain metastases (BMs), preferably by magnetic resonance imaging (MRI) or when contraindicated or not accessible a dedicated contrast enhanced–computed tomography (dCE-CT), which can be incorporated in the staging 18Fluodeoxoglucose–positron emission tomography (18FDG-PET-CE-CT). In daily practice, often a dCE-CT is performed instead of a MRI. The aim of the current study is to evaluate the additive value of MRI after dCE-CT, incorporated in the 18FDG-PET-CE-CT.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Janna Schoenmaekers, Paul Hofman, Gerben Bootsma, Marcel Westenend, Machiel de Booij, Wendy Schreurs, Ruud Houben, Dirk De Ruysscher, Anne-Marie Dingemans, Lizza E.L. Hendriks Tags: Original Research Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | CT Scan | Lung Cancer | MRI Scan | Neurology | Non-Small Cell Lung Cancer | PET Scan | Study